Merus MRUS 深 沪
已收盘 12-30 16:00:00 美东时间
90.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 90.00
- 总市值 68.21亿
- 52周最高 97.14
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 33.19
- 委 比 0.00%
- 总股本 7578.44万
- 历史最高 97.14
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.255
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio reported progress on its Phase 3 ELAINE-3 trial for lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with enrollment on track to complete by Q4 2026 and topline data expected in H2 2027. The company highlighted lasofoxifene's potential as a transformative treatment and discussed its favorable safety and efficacy profile from earlier studies. Financially, LeonaBio ended Q2 2026 with $51.1 million in cash ...
08-14 20:05
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
Zentalis Pharmaceuticals appoints Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy to strengthen commercial readiness as it advances azenosertib, a potential first-in-class WEE1 inhibitor, for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib is in late-stage development with a Phase 2 topline readout expected by year-end 2026 and a Phase 3 trial underway. The appoin...
05-27 20:05
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
LeonaBio, Inc. has expanded its Board of Directors with the addition of Fred Callori, Natalie Holles, and Peter B. Silverman, effective May 5, 2026, while John Fluke Jr. retired on May 4, 2026. The new members bring extensive experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets. Their expertise aligns with LeonaBio's focus on advancing its clinical pipeline for diseases with high un...
05-07 13:20
Merus Completes Genmab Acquisition and Delists From Nasdaq
Merus ( ($MRUS) ) has provided an update. On September 29, 2025, Merus N.V. ent...
2025-12-30 22:17
Genmab ends development of late-stage oncology asset acasunlimab
Genmab (GMAB) has decided to discontinue development of acasunlimab, which was in phase 3 for non-small cell lung cancer, to focus on other assets in its pipeline as well as its marketed product, Epki...
2025-12-29 23:07
健玛生物终止一款在研抗癌疗法研发
丹麦药企健玛生物（Genmab）周一宣布，将终止一款已进入后期临床试验的在研抗体抗癌疗法的研发工作。 2024 年，百欧恩泰（BioNTech）决定不再...
2025-12-29 22:11
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
Merus Acquired by Genmab, Leadership Changes Announced
An announcement from Merus ( ($MRUS) ) is now available. On December 11, 2025, ...
2025-12-12 21:18
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.
2025-11-19 01:58
